Daraxonrasib Improves Survival in Phase 3 Pancreatic Cancer Trial

Revolution Medicines announced practice-changing results from its phase 3 RASolute 302 trial, showing that its oral drug daraxonrasib significantly improved survival for patients with previously treated metastatic pancreatic cancer compared to standard chemotherapy.

The global trial, which enrolled patients regardless of identified RAS mutation status, met its primary endpoint of progression-free survival and key secondary endpoint of overall survival. In the intent-to-treat population, daraxonrasib reduced the risk of death by 60 percent, with median overall survival exceeding one year, or 13.2 months, versus 6.7 months for chemotherapy. Chairman and CEO Dr. Mark Goldsmith described the April topline readout as anchoring the company's progress, noting the drug was generally well tolerated with no new safety signals. Full results are set for presentation in a plenary session at the American Society of Clinical Oncology annual meeting.

Supporting phase 1/2 data, published this week in the New England Journal of Medicine, involved 168 patients with advanced RAS-mutated pancreatic ductal adenocarcinoma who had received prior therapy. At the 300-milligram daily dose planned for...